Bionano Symposium Highlights Growing Adoption of Optical Genome Mapping in Oncology and Cell Therapy
Event summary
- Bionano Symposium 2026, held February 25, 2026, featured 11 presentations focused on oncology and bioprocessing applications of Optical Genome Mapping (OGM).
- The symposium drew over 1,150 registered participants from 73 countries, marking it as the largest global event dedicated to Bionano solutions this year.
- Dr. Hippolyte Guerineau’s study of 214 multiple myeloma samples demonstrated OGM’s ability to reveal additional structural complexity compared to FISH.
- Dr. Ying Zou and Dr. Alejandro Berenguer Rubio’s research on rare sarcomas detected structural variants in over 70% of cases with normal karyotypes, revealing previously missed genomic rearrangements.
The big picture
Bionano’s OGM technology is positioned to capitalize on the growing demand for high-resolution genomic analysis in both oncology and cell/gene therapy. The presentations at Symposium 2026 underscore a shift towards more complex genomic profiling, moving beyond traditional methods like FISH and sequencing. However, widespread adoption hinges on demonstrating consistent clinical utility and navigating regulatory hurdles, particularly as applications expand into solid tumors.
What we're watching
- Adoption Rate
- The pace at which the FrOGG consortium’s standardization efforts and centralized data hub drive broader adoption of OGM across Europe and beyond will be a key indicator of Bionano’s long-term success.
- Regulatory Scrutiny
- How the FDA’s continued recognition of OGM’s utility in cell and gene therapy development impacts Bionano’s regulatory pathway and commercialization timelines warrants close monitoring.
- Solid Tumor Expansion
- Whether the momentum from the sarcoma studies can translate into broader adoption of OGM in other solid tumor types, expanding Bionano’s addressable market beyond hematological malignancies, remains to be seen.
Related topics